Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis

Rodrigo Jorge, Rogério A. Costa, Daniela Calucci, Ingrid U. Scott

Research output: Contribution to journalArticle

45 Scopus citations

Abstract

Purpose: To describe the clinical, angiographic, and optical coherence tomography findings of a patient with subretinal neovascularization (SRN) in idiopathic juxtafoveolar retinal telangiectasis (IJRT) treated with intravitreal bevacizumab injection. Methods: In the setting of a tertiary referral center, a patient with bilateral acquired IJRT, complicated with juxtafoveal SRN in one eye, was treated with a single intravitreal injection of 1.5 mg of bevacizumab and then prospectively followed for 24 weeks. Results: Vision improved from 20/40-1 to 20/20-2 by 24 weeks of follow-up. Fluorescein angiography demonstrated the absence of leakage from a previously active SRN. Optical coherence tomography revealed gradual neovascular lesion contraction and the resolution of subretinal fluid over the 24-week follow-up period. No obvious adverse events were noted. Conclusions: In the short-term, intravitreal bevacizumab treatment resulted in partial restoration of the macular architecture and vision improvement by means of neovascular lesion regression and the resolution of associated serohemorrhagic complications.

Original languageEnglish (US)
Pages (from-to)1045-1048
Number of pages4
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume245
Issue number7
DOIs
Publication statusPublished - Jul 2006

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this